CytomX Therapeutics to Present at Upcoming September Investor Conferences

Rhea-AI Summary

CytomX Therapeutics (Nasdaq: CTMX), a leader in masked, conditionally activated biologics, has announced its participation in two upcoming investor conferences in September 2024:

1. H.C. Wainwright 26th Annual Global Investment Conference: Scheduled for September 11, 2024, in New York, NY. CytomX will give a formal presentation at 12:30 p.m. ET.

2. 2024 Cantor Global Healthcare Conference: Set for September 19, 2024, also in New York, NY. The company will participate in a fireside chat at 9:45 a.m. ET.

Live webcasts of both events will be available on CytomX's website. The company's management will also be available for one-on-one meetings with registered conference attendees.

News Market Reaction – CTMX

+11.61%

1 alert

+11.61% News Effect

On the day this news was published, CTMX gained 11.61%, reflecting a significant positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

SOUTH SAN FRANCISCO, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will participate in the following investor conferences in September.

H.C. Wainwright 26^th Annual Global Investment Conference
Date: Wednesday, September 11, 2024
Formal Presentation: 12:30 p.m. ET
Location: New York, NY

2024 Cantor Global Healthcare Conference
Date: Thursday, September 19, 2024
Fireside Chat: 9:45 a.m. ET
Location: New York, NY

Live webcasts of the H.C. Wainwright presentation and Cantor fireside chat will be available on the Events and Presentations page of CytomX’s website at www.cytomx.com. In addition, management will be available for one-on-one meetings with investors who are registered to attend the conferences.

About CytomX Therapeutics
CytomX is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated, masked biologics designed to be localized to the tumor microenvironment. By pioneering a novel pipeline of localized biologics, powered by its PROBODY^® therapeutic platform, CytomX’s vision is to create safer, more effective therapies for the treatment of cancer. CytomX’s robust and differentiated pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (“ADCs”), T-cell engagers, and immune modulators such as cytokines. CytomX’s clinical-stage pipeline includes CX-904, CX-2051 and CX-801. CX-904 is a masked, conditionally activated T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells. CX-904 is partnered with Amgen in a global co-development alliance. CX-2051 is a masked, conditionally activated ADC directed toward epithelial cell adhesion molecule (EpCAM) and armed with a topoisomerase-1 inhibitor payload. CX-2051 has potential applicability across multiple EpCAM-expressing epithelial cancers and was discovered in collaboration with ImmunoGen, now part of AbbVie. CX-801 is a masked interferon alpha-2b PROBODY^® cytokine with broad potential applicability in traditionally immuno-oncology sensitive as well as insensitive (cold) tumors. CytomX has established strategic collaborations with multiple leaders in oncology, including Amgen, Astellas, Bristol Myers Squibb, Regeneron and Moderna. For more information about CytomX and how it is working to make conditionally activated treatments the new standard-of-care in the fight against cancer, visit www.cytomx.com and follow us on LinkedIn and X (formerly Twitter).

Company Contact:
Chris Ogden
SVP, Chief Financial Officer
cogden@cytomx.com

Investor Contact:
Precision AQ (formerly Stern Investor Relations)
Stephanie Ascher
stephanie.ascher@precisionaq.com

Media Contact:
Redhouse Communications
Teri Dahlman
teri@redhousecomms.com

FAQ

When is CytomX Therapeutics (CTMX) presenting at the H.C. Wainwright Global Investment Conference?

CytomX Therapeutics (CTMX) is presenting at the H.C. Wainwright 26th Annual Global Investment Conference on Wednesday, September 11, 2024, at 12:30 p.m. ET in New York, NY.

What time is CytomX Therapeutics (CTMX) participating in the Cantor Global Healthcare Conference?

CytomX Therapeutics (CTMX) is participating in a fireside chat at the 2024 Cantor Global Healthcare Conference on Thursday, September 19, 2024, at 9:45 a.m. ET in New York, NY.

Where can investors watch the webcasts of CytomX Therapeutics' (CTMX) conference presentations?

Live webcasts of CytomX Therapeutics' (CTMX) presentations at both conferences will be available on the Events and Presentations page of the company's website at www.cytomx.com.

Will CytomX Therapeutics (CTMX) management be available for one-on-one meetings at the September conferences?

Yes, CytomX Therapeutics (CTMX) management will be available for one-on-one meetings with investors who are registered to attend the conferences in September 2024.